NX-5948

· Nurix Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for NX-5948, covering 2025-03-12 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) [Phase 2]

See pricing